Clostridium difficile infection increases acute and chronic morbidity and mortality.


Journal

Infection control and hospital epidemiology
ISSN: 1559-6834
Titre abrégé: Infect Control Hosp Epidemiol
Pays: United States
ID NLM: 8804099

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 10 11 2018
medline: 18 12 2019
entrez: 10 11 2018
Statut: ppublish

Résumé

In this study, we aimed to quantify short- and long-term outcomes of Clostridium difficile infection (CDI) in the elderly, including all-cause mortality, transfer to a facility, and hospitalizations. Retrospective study using 2011 Medicare claims data, including all elderly persons coded for CDI and a sample of uninfected persons. Analysis of propensity score-matched pairs and the entire population stratified by the propensity score was used to determine the risk of all-cause mortality, new transfer to a long-term care facility (LTCF), and short-term skilled nursing facility (SNF), and subsequent hospitalizations within 30, 90, and 365 days. The claims records of 174,903 patients coded for CDI were compared with those of 1,318,538 control patients. CDI was associated with increased risk of death (odds ratio [OR], 1.77; 95% confidence interval [CI], 1.74-1.81; attributable mortality, 10.9%), new LTCF transfer (OR, 1.74; 95% CI, 1.67-1.82), and new SNF transfer (OR, 2.52; 95% CI, 2.46-2.58) within 30 days in matched-pairs analyses. In a stratified analysis, CDI was associated with greatest risk of 30-day all-cause mortality in persons with lowest baseline probability of CDI (hazard ratio [HR], 3.04; 95% CI, 2.83-3.26); the risk progressively decreased as the baseline probability of CDI increased. CDI was also associated with increased risk of subsequent 30-day, 90-day, and 1-year hospitalization. CDI was associated with increased risk of short- and long-term adverse outcomes, including transfer to short- and long-term care facilities, hospitalization, and all-cause mortality. The magnitude of mortality risk varied depending on baseline probability of CDI, suggesting that even lower-risk patients may benefit from interventions to prevent CDI.

Identifiants

pubmed: 30409240
pii: S0899823X18002805
doi: 10.1017/ice.2018.280
pmc: PMC6624072
mid: NIHMS1026354
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

65-71

Subventions

Organisme : AHRQ HHS
ID : R24 HS019455
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States

Références

J Clin Epidemiol. 2000 Dec;53(12):1258-67
pubmed: 11146273
Stat Med. 2009 Nov 10;28(25):3083-107
pubmed: 19757444
Infect Control Hosp Epidemiol. 2010 Mar;31(3):262-8
pubmed: 20100085
Pharm Stat. 2011 Mar-Apr;10(2):150-61
pubmed: 20925139
Health Serv Res. 2011 Feb;46(1 Pt 1):120-37
pubmed: 21029090
Clin Infect Dis. 2012 Jul;55(2):216-23
pubmed: 22491338
J Hosp Infect. 2012 May;81(1):1-14
pubmed: 22498638
Stat Med. 2014 Mar 30;33(7):1242-58
pubmed: 24122911
N Engl J Med. 2014 Mar 27;370(13):1198-208
pubmed: 24670166
PLoS One. 2014 Jun 04;9(6):e98400
pubmed: 24897375
Infect Dis Clin North Am. 2015 Mar;29(1):123-34
pubmed: 25677706
J Appl Gerontol. 2016 Mar;35(3):303-20
pubmed: 25698720
N Engl J Med. 2015 Feb 26;372(9):825-34
pubmed: 25714160
Clin Infect Dis. 2015 Dec 15;61(12):1781-8
pubmed: 26338788
Am J Infect Control. 2015 Nov;43(11):1148-53
pubmed: 26521932
Intern Emerg Med. 2016 Aug;11(5):657-65
pubmed: 26694494
PLoS One. 2016 Feb 09;11(2):e0146822
pubmed: 26859403
BMC Infect Dis. 2016 Apr 22;16:177
pubmed: 27102582
Infect Control Hosp Epidemiol. 2016 Sep;37(9):1068-78
pubmed: 27322606
Infect Control Hosp Epidemiol. 2016 Nov;37(11):1331-1336
pubmed: 27572289
Infect Control Hosp Epidemiol. 2017 Jan;38(1):45-52
pubmed: 27760583
Infect Dis Clin Pract (Baltim Md). 2015 Nov;23(6):318-323
pubmed: 27885315
PLoS One. 2017 Mar 3;12(3):e0172410
pubmed: 28257438
BMC Health Serv Res. 2017 May 30;17(1):376
pubmed: 28558756
J Hosp Infect. 2018 Jan;98(1):21-28
pubmed: 28712548

Auteurs

Margaret A Olsen (MA)

1Department of Medicine,Washington University School of Medicine,St Louis,Missouri.

Dustin Stwalley (D)

1Department of Medicine,Washington University School of Medicine,St Louis,Missouri.

Clarisse Demont (C)

3Sanofi Pasteur,Lyon,France.

Erik R Dubberke (ER)

1Department of Medicine,Washington University School of Medicine,St Louis,Missouri.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH